What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene…
What is Allogene Therapeutics, Inc.'s P/E and P/B ratio?
Allogene Therapeutics, Inc. has a P/E ratio of -1.9 and a P/B ratio of 0.99.
What is Allogene Therapeutics, Inc.'s debt-to-equity ratio?
Allogene Therapeutics, Inc. has a debt-to-equity ratio of 0.18.
How much does Allogene Therapeutics, Inc. owe compared with what it owns?
Allogene Therapeutics, Inc. owes $0.21 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Allogene Therapeutics, Inc.'s Positivity rank?
Allogene Therapeutics, Inc. is ranked #1,733 of 6,774 companies globally and #426 of 4,000 in United States on PositoAI, with a Positivity Score of 22,362.
Does Allogene Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Allogene Therapeutics, Inc..
Where can I read the latest news about Allogene Therapeutics, Inc.?
Recent headlines about Allogene Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Allogene Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Allogene Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.